APA (7th ed.) Citation

Croden, J., Garcia-Manero, G., Chien, K., DiNardo, C., Borthakur, G., Hammond, D., . . . Montalban-Bravo, G. (2026). A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia & Lymphoma, 67(7), 1580. https://doi.org/10.1080/10428194.2026.2650674

Chicago Style (17th ed.) Citation

Croden, J., et al. "A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia." Leukemia & Lymphoma 67, no. 7 (2026): 1580. https://doi.org/10.1080/10428194.2026.2650674.

MLA (9th ed.) Citation

Croden, J., et al. "A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia." Leukemia & Lymphoma, vol. 67, no. 7, 2026, p. 1580, https://doi.org/10.1080/10428194.2026.2650674.